Event Marks One-Year Anniversary of US Supreme Court Decision to Ban Human Gene Patenting
ME NewsWire/Business Wire
SAN DIEGO - Wednesday, June 18th 2014
Pathway
Genomics Corporation, a San Diego-based CLIA and CAP accredited
clinical laboratory that offers genetic testing services globally, last
week co-hosted a fundraiser benefiting Susan G. Komen. Jim Plante,
founder and CEO of Pathway Genomics, and Ryan Kavanaugh, CEO of
Relativity, were the hosts of the event, titled Pathway to the Cure. The
fundraiser, held in Santa Monica, California, raised more than $300,000
through generous donations made by attendees of the event.
“We’re
working with Susan G. Komen to help spread awareness about breast
cancer, and to help as many women as we can in the battle against this
disease,” said Plante. “We’re truly working to save lives, and
ultimately prevent breast cancer forever.”
Attended by notable
celebrities, such as Adrian Grenier and Sophia Bush, the event’s
entertainment for the evening was provided by DJ Zen Freeman and DJ
Nikki Pennie, and included a musical performance by world-renowned
artist Kesha, whose hits include “Tik Tok,” and the wildly popular
“Timber,” a collaboration with rapper Pitbull.
“This was an
extraordinary event. We are grateful for the commitment and generosity
of supporters such as Relativity and Pathway Genomics that will help us
save lives in California and around the world, ” said Susan G. Komen
president and CEO, Judith A. Salerno, M.D., M.S.
The fundraiser
comes at the one-year anniversary of the U.S. Supreme Court’s unanimous
decision to ban the patenting of naturally occurring genes, such as
BRCA, the gene linked to breast cancer. “We firmly believe that genetic
testing for the risk of breast cancer is every person’s right and should
not be overpriced and monopolized by massive corporations,” said
Plante. “Pathway’s BRCA test price and our BRCA One for One program is a
testament to this dedication to serve those who cannot afford this
potentially life-saving test.”
Earlier this month, Pathway
Genomics launched its next-generation sequencing and
deletion/duplication analysis, BRCATrueTM, which can detect mutations in
BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of
cancer. BRCATrue has a sensitivity of >99.99% and the broadest
coverage across BRCA1/2 in the industry. To enhance the accessibility of
the test, the company also launched the first-of-its-kind BRCA One for
OneTM program – for every qualified BRCATrue test ordered, one test is
donated to a person in need through patient advocacy organizations, up
to $10 million of free testing.
To learn more about BRCATrue,
visit www.pathway.com/brcatrue. For more details about the BRCA One for
One program, visit www.brcaoneforone.com.
About Pathway Genomics
Corporation As a CLIA and CAP accredited clinical laboratory based in
San Diego, California, Pathway Genomics provides physicians and their
patients with actionable and accurate genetic information to improve or
maintain health and wellness. Since its founding in 2008, Pathway
Genomics has become known for its dedication to innovation and
commitment to medical responsibility – making it a leader in the
commercial genetic testing industry. Pathway Genomics’ testing services
cover a variety of conditions including cancer risk, cardiac health,
inherited diseases, nutrition and exercise response, as well as drug
response for specific medications including those used in pain
management and mental health. For more about Pathway Genomics, visit
www.pathway.com.
About Susan G. Komen Susan G. Komen is the
world’s largest breast cancer organization, funding more breast cancer
research than any other nonprofit while providing real-time help to
those facing the disease. Since its founding in 1982, Komen has funded
more than $800 million in research and provided $1.7 billion in funding
to screening, education, treatment and psychosocial support programs
serving millions of people in more than 30 countries worldwide. Komen
was founded by Nancy G. Brinker, who promised her sister, Susan G.
Komen, that she would end the disease that claimed Suzy’s life. Visit
komen.org or call 1-877 GO KOMEN. Connect with us on Facebook at
facebook.com/susangkomen and Twitter @SusanGKomen.
About
Relativity Relativity (relativitymedia.com) is a next-generation global
media company engaged in multiple aspects of content production and
distribution, including movies, television, fashion, sports, digital and
music. More than just a collection of entertainment-related businesses,
Relativity is a content engine with the ability to leverage each of
these business units, independently and together, to create content
across all mediums, giving hundreds of millions of users worldwide what
they want, when they want it.
Relativity Studios, the company’s
largest division, has produced, distributed or structured financing for
more than 200 motion pictures, generating more than $17 billion in
worldwide box-office revenue and earning 60 Oscar nominations.
Relativity’s films include Oculus, Safe Haven, Act of Valor, Immortals,
Limitless, and The Fighter. Upcoming releases include Earth to Echo and
author Nicholas Sparks’ The Best of Me.
Contacts
Pathway Genomics Corporation
Zak Pugh, 858-217-4358
pr@pathway.com
www.pathway.com
Permalink: http://www.me-newswire.net/news/11359/en
No comments:
Post a Comment